J Bacteriol Virol.  2018 Jun;48(2):67-71. 10.4167/jbv.2018.48.2.67.

NLRC3 Attenuates Colon Cancer by Down-Regulating PI3K-mTOR Signaling

Affiliations
  • 1Department of Microbiology and Immunology, School of Medicine and Brain Korea 21 PLUS Program, and Jeju Research Center for Natural Medicine, Jeju National University, Jeju, Korea. yskoh7@jejunu.ac.kr

Abstract

The nucleotide-binding oligomerization domain-like receptors (NOD-like receptors, NLRs) are intracellular sensors. Most of them positively affect inflammatory responses, particularly the inflammasome forming NLRs. On the other hand, several studies on gene-deficient mice have revealed that several NLRs negatively influence innate immune responses. Some recent studies have identified a novel sub-group of non-inflammasome forming NLRs that negatively influence different pathways related to inflammation and carcinogenesis. Cytosolic pattern recognition receptor NRLC3 is a negative regulator of innate immune response. In this review we will discuss finding related with NLRC3 and its mechanism by which it alter cancer pathogenesis. Recently, it has been found that mice deficient in Nlrc3 are hyper-susceptible to colitis and colitis-associated colon carcinogenesis. Oncogenic inhibitory effect of NLRC3 is more dominant in epithelial compartment than hematopoietic compartment. It down regulates mTOR signaling and reduce cell proliferation. NLRC3 interact with PI3Ks and suppress activation of PI3K dependent kinase AKT. Understanding the role of NLRC3 in cancer may facilitate the recognition of new therapeutic strategies.

Keyword

NLRC3; mTOR; Colon cancer

MeSH Terms

Animals
Carcinogenesis
Cell Proliferation
Colitis
Colon*
Colonic Neoplasms*
Cytosol
Hand
Immunity, Innate
Inflammasomes
Inflammation
Mice
Phosphotransferases
Inflammasomes
Phosphotransferases
Full Text Links
  • JBV
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr